Research Papers

GLP -1 Agonists Influence Gut Microbiota and Metabolic Health

Published: 2021
Source: Frontiers in Endocrinology
Focus: Reviewing studies on the interaction between GLP-1 agonists, obesity, and gut microbiota.
Study Design: Comprehensive review of existing human studies.
Findings: GLP-1 agonists have been associated with changes in gut microbiota composition, such as increased levels of beneficial/commensal bacteria, which may enhance insulin sensitivity.
Key Insights: The modulation of gut microbiota by GLP-1 agonists offers a promising strategy for improving metabolic health and managing obesity.

Supplementation Enhances GLP -1 Secretion

Published: 2020
Source: Nature Medicine
Focus: Evaluating the effects of supplementation of specific commensal bacteria on GLP-1 secretion and metabolic health.
Study Design: Randomized, double-blind, placebo-controlled trial with human participants.
Findings: Supplementation with specific commensal bacteria increased GLP-1 and peptide YY levels, leading to reduced appetite and body weight.

Crosstalk Between Glucagon-Like Peptide -1 and Gut Microbiota in Metabolic Diseases

Published: August 2021
Source: Frontiers in Endocrinology
Focus: Exploring the bidirectional interactions between GLP-1 and gut microbiota, and their implications for metabolic diseases.
Study Design: Review of existing literature on the interactions between GLP-1 and gut microbiota.
Findings: Gut microbiota metabolites, such as short-chain fatty acids (SCFAs), stimulate GLP-1 secretion, influencing glucose metabolism and appetite regulation. Conversely, GLP-1 affects the composition and function of gut microbiota, suggesting a complex interplay that impacts metabolic health.
Key Insights: Understanding this crosstalk offers potential therapeutic avenues for treating metabolic disorders through modulation of both GLP-1 pathways and gut microbiota composition.

Published: 2023
Source: Nutrients
Study Design: Randomised, double-blind, placebo-controlled trial involving 63 overweight and obese adults over 12 weeks. Participants received either a multispecies synbiotic supplement (combining seven probiotic strains with fructooligosaccharides) or a placebo.
Findings: The synbiotic group exhibited a significant reduction in waist circumference and body fat percentage compared to baseline. Additionally, there was a notable decrease in Firmicutes abundance and the F/B ratio at week 12 compared to the placebo group.
Key Insights: Synbiotic supplementation may beneficially modulate gut microbiota composition, particularly by reducing the F/B ratio, which is associated with improvements in body composition among overweight and obese individuals.

Published: 2021
Source: Paediatric Obesity
Study Design: Randomised, double-blind, placebo-controlled pilot study involving 15 adolescents with severe obesity over 12 weeks. Participants received either the probiotic or a placebo.
Findings: The probiotic group showed a greater decline in the F/B ratio from baseline to week 12 compared to the placebo group, although the difference was not statistically significant (p = 0.06). Additionally, the probiotic group had a significant improvement in fasting glucose levels.
Key Insights: Probiotic supplementation may influence gut microbiota composition and metabolic parameters in adolescents with severe obesity, warranting further investigation in larger studies.

Published: 2024
Source: Frontiers in Nutrition
Study Design: Randomised, double-blind, placebo-controlled trial involving 80 obese adults over 12 weeks. Participants received either a synbiotic supplement or a placebo.
Findings: The synbiotic group experienced significant reductions in body fat percentage, waist circumference, and serum LDL cholesterol. While specific changes in the F/B ratio were not detailed, the intervention led to favourable shifts in gut microbiota composition.
Key Insights: Synbiotic supplementation may improve body composition and lipid profiles in obese individuals, potentially through modulation of gut microbiota.

Published: 2023
Source: Obesity
Study Design: Randomised, double-blind, placebo-controlled trial involving 172 overweight and obese adults over 12 weeks. Participants were assigned to receive one of two synbiotic formulations or a placebo.
Findings: Both synbiotic groups showed significant reductions in BMI and body weight compared to the placebo group. Improvements in HDL cholesterol and reductions in high-sensitivity C-reactive protein levels were also observed.
Key Insights: Synbiotic supplementation may effectively reduce body weight and improve metabolic health markers in overweight and obese individuals.

Let's Connect